EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment

Enrico Bellato, Eleonora Marini, Filippo Castoldi, Nicola Barbasetti, Lorenzo Mattei, Davide Edoardo Bonasia, Davide Blonna

Pain Research and Treatment · 04.11.2012 · 2012 · 1-17

DOI: 10.1155/2012/426130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Research and Treatment, erschienen am 04.11.2012. Verfasst von Enrico Bellato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics and Traumatology, Mauriziano Umberto I Hospital, University of Turin Medical School, Largo Turati 62,10128 Turin, Italy [co…. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibromyalgia syndrome is mainly characterized by pain, fatigue, and sleep disruption. The etiology of fibromyalgia is still unclear: if central sensitization is considered to be the main mechanism involved, then many other factors, genetic, immunological, and hormonal, may play an important role. The diagnosis is typically clinical (there are no laboratory abnormalities) and the physician must concentrate on pain and on its features. Additional symptoms (e.g., Raynaud’s phenomenon, irritable bowel disease, and heat and cold intolerance) can be associated with this condition. A careful differential diagnosis is mandatory: fibromyalgia is not a diagnosis of exclusion. Since 1990, diagnosis has been principally based on the two major diagnostic criteria defined by the ACR. Recently, new criteria have been proposed. The main goals of the treatment are to alleviate pain, increase restorative sleep, and improve physical function. A multidisciplinary approach is optimal. While most nonsteroidal anti-inflammatory drugs and opioids have limited benefit, an important role is played by antidepressants and neuromodulating antiepileptics: currently duloxetine (NNT for a 30% pain reduction 7.2), milnacipran (NNT 19), and pregabalin (NNT 8.6) are the only drugs approved by the US Food and Drug Administration for the treatment of fibromyalgia. In addition, nonpharmacological treatments should be associated with drug therapy.

Autor:innen und Institutionen

  • Department of Orthopedics and Traumatology, Mauriziano Umberto I Hospital, University of Turin Medical School, Largo Turati 62,10128 Turin, Italy [corrected].

Zitieren

APA

Bellato, E., Marini, E., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, D. E., & Blonna, D. (2012). Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment. Pain Research and Treatment, 2012, 1-17. https://doi.org/10.1155/2012/426130

Vancouver

Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment. Pain Research and Treatment. 2012;2012:1-17. doi:10.1155/2012/426130

BibTeX
@article{Bellato2012,
  author = {Bellato, Enrico and Marini, Eleonora and Castoldi, Filippo and Barbasetti, Nicola and Mattei, Lorenzo and Bonasia, Davide Edoardo and Blonna, Davide},
  title = {Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment},
  journal = {Pain Research and Treatment},
  year = {2012},
  volume = {2012},
  pages = {1--17},
  doi = {10.1155/2012/426130}
}
Kostenlos starten →